Commercialization of your project will receive the lift it needs through our
worldwide manufacturing footprint with its global reach and comprehensive tech
transfer capabilities. Our strengths can be shared across the spectrum of
pharmaceutical and biopharmaceutical custom manufacturing services ensuring
you receive what you need, when you need it, and on time to market.
For our biopharmaceutical customers, our Groningen, Netherlands manufacturing
facility offers the scope and infrastructure necessary to meet your
needs. Whether you’re delivering monoclonal antibodies or proteins, Groningen
has the integrated approach to biopharmaceutical production that guarantees a
quality product.
At our Venlo, Netherlands facility our research and development teams and
manufacturing staff bring you a breadth manufacturing services in the
pharmaceutical and biopharmaceutical arena. Our menu includes chiral
synthesis, biocatalysis, Grignard reactions, Friedel & Crafts reactions,
bromination, chlorination, aromatic substitutions, metal hydride reductions.
A part of DSM since 1987, the facility offers customers a state-of-the-art
production and pilot plant, a biological waste water treatment plant, off-gas
incineration, and an R&D and pilot plant. Through 44 reactors, Venlo is able
to deliver total reactor volume of 176 m³.
Our commercial capabilities within the pharma chemicals arena extends even
further through our Linz, Austria facility. Offering a customers a broad
choice of manufacturing capabilities our types of plants include:
multipurpose plants, multiproduct ozonolysis plant, glyoxylic acid plants and
an esterfification plant. Additional facilities include R&D, (cGMP) Pilot
Plant and Engineering at site, ISO 9001 approved MP facilities, Biological
waste water treatment and modern high shelf storage. Formerly Chemie Linz,
Linz has been part of DSM since 1996.
In the United States, our Greenville, North Carolina facility drives our
services in the sterile fill finish and orals and topicals environments. A
premier facility of DSM, Greenville offers customers manufacturing services
including hydrogenation, metal hydride reductions, organometallic reactions
bromination, chlorination, substitution, sodium azide chemistry, asymmetric
catalytic reductions, Heck, Grignard and organolithium reactions. Former Glaxo
Wellcome site, Greenville has been part of DSM since 2000 and include three
cGMP, multipurpose plants (10 production trains), a hydrogenation plant, an
R&D and pilot plant, FDA approved multi purpose facilities, waste water
treatment plant and 5 incinerators. Greenville offers customers 61 reactors
with a total reactor volume of 185 m³.
